{"name":"United Therapeutics","slug":"united-therapeutics","ticker":"","exchange":"","domain":"united.com","description":"United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; and Manchester, New Hampshire.","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":1483300000,"revenueGrowth":2.4,"grossMargin":0,"rdSpend":550000000,"netIncome":1334700000,"cash":7880000000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2020"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"GGTA1 KO Thymokidney","genericName":"GGTA1 KO Thymokidney","slug":"ggta1-ko-thymokidney","indication":"Other","status":"phase_1"},{"name":"Intravenous Treprostinil","genericName":"Intravenous Treprostinil","slug":"intravenous-treprostinil","indication":"Other","status":"marketed"},{"name":"ch14.18 -NCI","genericName":"ch14.18 -NCI","slug":"ch14-18-nci","indication":"Other","status":"phase_1"},{"name":"ch14.18-UTC","genericName":"ch14.18-UTC","slug":"ch14-18-utc","indication":"Other","status":"phase_1"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"prostacyclin","genericName":"prostacyclin","slug":"prostacyclin","indication":"Allergic rhinitis","status":"marketed"}]}],"pipeline":[{"name":"GGTA1 KO Thymokidney","genericName":"GGTA1 KO Thymokidney","slug":"ggta1-ko-thymokidney","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Intravenous Treprostinil","genericName":"Intravenous Treprostinil","slug":"intravenous-treprostinil","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ch14.18 -NCI","genericName":"ch14.18 -NCI","slug":"ch14-18-nci","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ch14.18-UTC","genericName":"ch14.18-UTC","slug":"ch14-18-utc","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"prostacyclin","genericName":"prostacyclin","slug":"prostacyclin","phase":"marketed","mechanism":"P2Y purinoceptor 12, Prostacyclin receptor, Prostaglandin E2 receptor EP1 subtype","indications":["Allergic rhinitis","Common cold","Cough","Nasal congestion","Nasal discharge"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxONjZVVUR2R2JGRUQ5Z3NvZ0FFLUNtQ2NHYnRCNk1qRHZYUGx3MFFwZkNaRTNZNm1qczBIOEVubkdwcjNUWDR6VlR5cnFud205d0NMSGZGcWdsYWpkRzBHdTRKT1NxNlZZNFNVN29CVHE4VVdxanBYMTFEcXNaaGVaODNMOXh2SElVWGxWRUxoV3F2YV8zTFlVeVc0MGwxQTdvZlBWLWNOcTkwdVBVaE5maTk0ODJSYUJtMURxQWJXVXlCdHYx?oc=5","date":"2026-03-30","type":"regulatory","source":"Fierce Pharma","summary":"United plots Tyvaso FDA filing after ph. 3 win elicits talk of 'new IPF standard' and blockbuster sales - Fierce Pharma","headline":"United plots Tyvaso FDA filing after ph. 3 win elicits talk of 'new IPF standard' and blockbuster sales","sentiment":"neutral"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNUWxRYVRNYkUxaEdiVFp3a1h1N2V6V09YVmpKLWdhX1R3TjdrS09DaDlLZURVcWJLWlJqYkt2OTQxVkE2QVlkNzdfaUE3NXI2WjU5STFnZ1FJVVk2clJqc0o5MEVrVjF5TFFYdWlDUlZOYnlMMDhCbFRUX0pfa08yeUhOWmc4RTZMMjlGNkNxZFBHQWRfbFlHcEhUVVZYbElKREp5Y0VyV0dpYzBYRHhseGh3NDRRUQ?oc=5","date":"2026-03-03","type":"pipeline","source":"The Pharma Letter","summary":"United Therapeutics’ ralinepag reduced risk of clinical worsening in PAH - The Pharma Letter","headline":"United Therapeutics’ ralinepag reduced risk of clinical worsening in PAH","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-03","type":"trial","source":"ET Pharma","summary":"United Therapeutics' drug for rare lung disease succeeds in late-stage study - ET Pharma","headline":"United Therapeutics' drug for rare lung disease succeeds in late-stage study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQZWFQVkJMb1ZuaXF2dDhZclRSRTJKWEJqV1h5dklRc00wdUtpZlhuRTBZc0xjcnZ4VXFKbVU5Wnk5TmVnZklmczZlYXpuMHJGVFJOY01sYTNDa3l3Q053eC1hMmswMkVaZ0V3WXhQYmhKTndJVGxTMGZ6ZWl2R1ZTcmNhU1l2LUx0cWZ4d3E0cDNUdURmamVRbjVNOXJ3bW05?oc=5","date":"2026-03-02","type":"regulatory","source":"Endpoints News","summary":"United Therapeutics to take pulmonary hypertension drug to FDA for approval - Endpoints News","headline":"United Therapeutics to take pulmonary hypertension drug to FDA for approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOWnRSNXJJMWRjdVRNY3dCWmluRm0zWG5BRGZjUnVHUXUtcVpiMHpkZFNIQ2IzN3c1T2hqZ3AtNDJJUnpfajhZOFZHRDNLczhJckhWVGVrWmdiejR4TFMyUjVBVldHdGZESkVvTENueHdIVnBhOWlrR09NUXJIeG56QktxYWNPZUlqdnI0?oc=5","date":"2026-03-02","type":"trial","source":"pharmaphorum","summary":"United's PAH drug clears phase 3 trial, setting up filings - pharmaphorum","headline":"United's PAH drug clears phase 3 trial, setting up filings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNMUgwN09vMG5JSzl0S2duTmFpR0pUc0JWdjEwX1d0MUVlT2FYQnZ6cHZoWGFuMHdCbTF6eFkxSHY1N3BpTHR3MFBkdHBYZUNmTDNOQW1nbXBGNGx1aXQxRVNHcl9YRnVRcTNGLUU3ZW1aOEtNc05xSGdtNkhERVg2bjBicEJhc01EakI0dW1GeGlaWE50QzlRandaNjBrNllGS2hJbG5ndy1yb1d4cGtrdUxyci1LR2hiS21SR253bGpteUE?oc=5","date":"2026-02-08","type":"pipeline","source":"AD HOC NEWS","summary":"The Truth About United Therapeutics: Why Wall Street Can’t Stop Watching UTHR - AD HOC NEWS","headline":"The Truth About United Therapeutics: Why Wall Street Can’t Stop Watching UTHR","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTFBrNENRQ3BfZzVIUkVSeTdmRHF6dkpfekJuZjBHUUtfeDFKemJWdmpIZ25jUDBHUjVLSWNDeG5Vam1pMl82QnJ6cWFURHAweW9qWURETFlaMmNEOFVjdnRSTnBfUTJiMDdpSFBLSm52NUpFNFhyZ0hn?oc=5","date":"2026-01-24","type":"pipeline","source":"Nanalyze","summary":"The Best Pharma Stock I’ve Ever Seen - Nanalyze","headline":"The Best Pharma Stock I’ve Ever Seen","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOZlVhTXdSVEI3RHZaYjl0UHBfUnI4M2VHZWJBQVhwaDFxcFUxU1VLN2tUeWZOTDdrT21UM3BsZFI1RnNza3ZXN2ZDc3VmaTgxMmtRYzN6MlVFcjZoaUpNMHNGclBVMWlUbG85bXpoNUxGSnM0Szl3dE5lOURkUC1TOEp5YnVmNmQyWnp4VG1QOFJsbFF2VVgtSzhGWi0wbXd1eTdXM1ZR?oc=5","date":"2025-09-19","type":"pipeline","source":"The Business Journals","summary":"RTP campus sold for $107 million - The Business Journals","headline":"RTP campus sold for $107 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE12ZVdfTmh4QU0xWUEybHVMa2NvN2RBWENJM3pUbFVvUVJlR2lqekt5QUZ2TVlUc0NsbWdIRUlDQ1NKUS1MWl9fbDB6cjNZLUlQT3k4?oc=5","date":"2025-09-02","type":"trial","source":"FirstWord Pharma","summary":"United soars as inhaled treatment exceeds expectations in pivotal IPF study - FirstWord Pharma","headline":"United soars as inhaled treatment exceeds expectations in pivotal IPF study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxPV2daRFhZMXZTS0d1Wjh5SG8yZlk3dzh2bk1KTDZ6NlFRU3htcHFNYTJLUm51YVIyeTNZQnpCcmNPLW9vOGIxNmM4and4R1liNjVpOXZ6NURLWDRiMDR5SldBeW5uczFSeUpFbGYtUWJFdmIxNnJBbXo4TU1LLWZ1a3YzTndCZ3FRbEFQS2Z1VGhaVzdYWFBxeWxFUUtlWWtTZFJiSlJZdXRhUmxUbDJGUHptTVlEcGhwVzRjNnE4VkZsWE9UaUdpNkxVbmF0VWJuc0pydEdCSlFMdmVFN19zTFFna3M5bF85VkpaU3pQMWhMMWs?oc=5","date":"2025-09-02","type":"pipeline","source":"Stocktwits","summary":"This Pharma Stock Soared 36% Today And Drew Price Target Hikes From Wall Street – More Details Inside - Stocktwits","headline":"This Pharma Stock Soared 36% Today And Drew Price Target Hikes From Wall Street – More Details Inside","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOQUljcVR4bTUyUHFfSmhxbWxWNUJvRU9qWDd3VjBpWERObXo0Y1NRZEM2eUdtTlI3aEZVcjVNM1FWVzNBeFlIcUNlcGo2eWROT2ZZekc4SVJkUUtRYkN5WmQySFFZaFA5NEs3ZUllQjJrZm9kLU41dF96SGNnWjRqVk1KVktXVzlrbTJ6MjdId0J0NGFGcGtiQWZiMzRRRG5YU013M0VfeWYtZ21TZ0FRSDNrYXJ4bTl6V0JkWGhNTUJ2QW8?oc=5","date":"2025-09-02","type":"trial","source":"Fierce Pharma","summary":"United plots Tyvaso lung disease expansion with 'overwhelmingly positive' trial win - Fierce Pharma","headline":"United plots Tyvaso lung disease expansion with 'overwhelmingly positive' trial win","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOdTJZLTlodjl4Nmo0MV9xTms2UVRnVHZZNHpPWWZwTWk2QXh2Sk5nYkY1alhqejRJbXJOVktwVE8tbm9OSHEyZWRrTjBkb29tcXFUR011TDZjVndWVmVkR2ZwTGNQWmM4Z0pQN1RKMU54RkpaUktibHQzRUEtWUhQVTNjX0lKUHJWa1RoS3Q5R0ZobDhKTDd3?oc=5","date":"2025-07-21","type":"trial","source":"Yahoo Finance","summary":"United Therapeutics Corporation (UTHR) Completes Phase 3 Enrollment for Promising PAH Drug Ralinepag - Yahoo Finance","headline":"United Therapeutics Corporation (UTHR) Completes Phase 3 Enrollment for Promising PAH Drug Ralinepag","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_1":3,"marketed":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":1483300000,"revenuePeriod":"2020-12-31","revenueHistory":[{"value":1483300000,"period":"2020-12-31"},{"value":1448800000,"period":"2019-12-31"},{"value":1448800000,"period":"2019-12-31"},{"value":311100000,"period":"2019-12-31"},{"value":401500000,"period":"2019-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":550000000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":1334700000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":7880000000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}